Australian and New Zealand Massive Transfusion Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMonash University

About this trial

Severe and un-stopped blood loss can occur for a number of different reasons including after a serious injury, delivery of a baby and following other medical and surgical emergencies. The investigators understanding of how to best treat people with serious bleeding is still incomplete, with many questions remaining. These include questions regarding how many people have serious bleeding events, what happens to them and the best way to treat them.

The Massive Transfusion Registry (MTR) is a register of patients who have experienced major blood loss that required a massive transfusion in any clinical setting.

The MTR uses electronic data extraction and data linkage methodologies. Pre-existing clinical data from hospital data sources, including Laboratory Information Systems (for transfusion history and laboratory results) and Health Information Services databases (for Patient demographics and admission data), are electronically extracted by staff employed at the participating hospitals. The data is then sent to the MTR Research Team, located at Monash University, where it is then linked, analysed and stored.

The establishment of a Massive Transfusion Registry will be a unique and important resource for clinicians in Australia, New Zealand and internationally, for Blood Services and for the broader community. It will provide valuable observational data regarding the types and frequency of conditions associated with critical bleeding requiring massive transfusion, the use of blood component therapy (i.e. ratios and quantities of different types of red cell to non- red cell components) and patient outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

aged 18 years or over

5 or more units of red blood cells in any 4 hour period

Disqualifiers

nil

Trial population

All patients admitted to participating hospitals, aged 18 years or over, who have had a critical bleeding event that necessitated a massive transfusion (defined as 5 or more units of red blood cells in any 4 hour period), in any clinical context.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

50,000 Participants
are grouped into 1 trial group
Group A: Massively transfused patients

Trial outcomes

Primary outcomes

1

Mortality

Time frame
30 days

Secondary outcomes

Other outcomes

1

Blood product use

Trends in blood products transfused at 48 hours across various bleeding types

Time frame
48 hours

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Monash University

Lead sponsor

CSL Behring

Collaborator

Department of Health and Human Services Victoria

Collaborator

National Blood Authority

Collaborator

New Zealand Blood Service

Collaborator